Medium-Chain Triglycerides for Health & Longevity - Quick Reference Sheet

Medium-Chain Triglycerides for Health & Longevity

Created on 08/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Fats burned fast, turning partly into ketones — fuel for brain and muscle. Small thinking-score gains appear where memory is already slipping, and strength gains in the very frail; midlife is untested. Loose stools fade with slow escalation. Blood fats depend on what the oil replaces: favorable against butter, not olive oil. Added rather than swapped, simply extra calories. (Full Review)

Protocol

Standard maintenance dose
15–30 g daily
Combined caprylic and capric acid. Frailty and sarcopenia trials used 6 g daily. Adults over 75 generally start at 2.5–5 mL.
Best time of day
Fasted morning
Largest ketone peak, since carbohydrate blunts ketogenesis. Evening dosing was tested in the frailty trials with equally good functional results.
Split versus single dosing
2–3 divided doses
Sustains ketones across waking hours and stays below the gastrointestinal threshold. Single large doses suit acute cognitive or exercise timing.
Time to effect
Cognition
1–6 months
Functional endpoints lag far behind the ketone rise, and no controlled data exist beyond six months.
Muscle strength
12 weeks
Gains regressed toward baseline within six weeks of stopping, so they depend on continued intake.
Blood ketones
30–120 minutes
Ketones rise within 30–120 minutes of the first dose and fall toward baseline by three to four hours.

Benefits

Contraindications
  • Medium-chain acyl-CoA dehydrogenase deficiency or any medium-chain fatty-acid oxidation disorder
  • Decompensated cirrhosis (Child-Pugh Class C) or any history of hepatic encephalopathy
  • Type 1 diabetes, or type 2 diabetes with prior diabetic ketoacidosis
  • Severe hypertriglyceridemia (fasting triglycerides >500 mg/dL) until treated
  • Pregnancy, at supplemental doses above culinary amounts
  • Acute pancreatitis, or the first three months after an episode
Key Interactions
  • Sodium-glucose cotransporter-2 inhibitors (canagliflozin, empagliflozin, dapagliflozin)
  • Insulin and sulfonylureas (glipizide, glimepiride)
  • Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide)
  • Exogenous ketone salts and esters
  • Ketogenic diet and prolonged fasting
  • Magnesium-containing antacids and laxatives
  • Soluble fiber supplements (psyllium, acacia)
  • Orlistat

Risk & Side Effects

  • High: Gastrointestinal intolerance; adverse blood lipid shifts
  • Medium: Weight gain when added rather than substituted
  • Low: Hepatic strain at high habitual intake
  • Speculative: Hepatic encephalopathy in advanced cirrhosis; ketoacidosis alongside sodium-glucose cotransporter-2 inhibitors; gut microbiome disruption

Monitoring

Marker Target Why
Fasting triglycerides 50–90 mg/dL The lipid most consistently raised
ApoB <80 mg/dL, <60 if high cardiovascular risk Counts atherogenic particles directly
LDL cholesterol 70–100 mg/dL Rises when these fats displace unsaturated oils
HDL cholesterol ≥50 mg/dL in men, ≥60 mg/dL in women Rises relative to long-chain saturated fat
Fasting insulin and HOMA-IR Insulin 2–5 μIU/mL; HOMA-IR below 1.5 Tracks the insulin-sensitivity signal seen in overweight adults
HbA1c 4.8–5.4% Confirms no glycemic drift from the dietary change
Capillary beta-hydroxybutyrate 0.3–1.0 mmol/L at 60–120 minutes post-dose Confirms the dose is actually producing ketones
ALT 10–26 U/L in men, 10–19 U/L in women Screens for hepatic strain at high habitual intake
hs-CRP Below 1.0 mg/L Baseline for the unproven inflammatory claim
Body composition No established target; track change from the individual's own baseline Distinguishes fat loss from lean-mass loss
Grip strength ≥35 kg in men, ≥20 kg in women The function endpoint the frailty trials moved

Cadence: Capillary ketone check 90 minutes after a dose during the first week; full lipid and metabolic panel at 8–12 weeks, then every 6–12 months while intake continues; body composition and grip strength at 12 weeks, then annually.

Qualitative Assessment

  • Stool consistency and frequency during titration, the earliest signal that the dose is too high
  • Subjective mental clarity and sustained focus in the two to four hours after a dose
  • Perceived energy stability across a fasted morning, compared with the pre-supplementation pattern
  • Appetite and spontaneous eating volume at the meal following a dose
  • Ease of stair climbing, chair rise and carrying tasks, tracked monthly rather than daily
  • Sleep onset latency and night-time bowel urgency, particularly with evening dosing